Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not ...

All dose groups demonstrated good safety and tolerability versus placebo, with similar adverse event (AE) incidence (70% vs. 85%). At the recommended Phase IIb dose (RP2D), the annualized rate of ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). A mix of ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Vitamin D supplementation prevented moderate to severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with vitamin D deficiency in a multicenter, double-blind, randomized ...